Observational studyChinese journal of traumatology = Zhonghua chuang shang za zhi2026
Real-world use of monoclonal anti-tetanus toxin antibody for post-traumatic passive immunization: A nationwide survey in China.
Observational study in Chinese journal of traumatology = Zhonghua chuang shang za zhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the current status of monoclonal anti-tetanus toxin antibody used for passive immunization in the prevention and management of post-traumatic tetanus in China, and to provide evidence for the selection of passive immunization agents for tetanus prophylaxis.
methodsThis retrospective, multicenter, real-world survey included patients who received a monoclonal anti-tetanus toxin antibody (siltartoxatug injection) for passive immunization following traumatic injury at participating hospitals across China between March 1 and August 20, 2025. Patients with incomplete registration data or at least 1 missing key variable were excluded. Demographic, clinical, wound-related, payment, and follow-up information was collected. According to the National Clinical Practice Guideline for Non-neonatal Tetanus Prevention and Treatment (2024 Edition), patients were classified into high- and low-risk tetanus exposure groups based on vaccination history, booster interval, wound characteristics, and immune status. Demographic, clinical, and wound-related characteristics were compared between the 2 groups. Statistical analyses were performed using IBM SPSS Statistics, version 26.0 (IBM Corp., Armonk, NY, USA). Categorical variables were presented as frequencies and percentages and compared using the chi-square test or Fisher's exact test, as appropriate. All statistical tests were two-sided, and a p value < 0.05 was considered statistically significant.
resultsA total of 423 hospitals from 28 provinces, autonomous regions, and municipalities participated in the survey and provided case data. Among 1474 patients who received monoclonal anti-tetanus toxin antibody for passive immunization following trauma, no tetanus cases were documented during the available observation period; however, follow-up duration was not standardized across centers, and the protective efficacy of the monoclonal antibody could not be definitively evaluated.
conclusionStandardized wound assessment and appropriate selection of passive immunization agents are crucial for tetanus prevention. Monoclonal anti-tetanus toxin antibody represents an effective and promising option for passive immunization against tetanus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.